Neoadjuvant Chemotherapy for Locally Advanced Thymic Cancer

Samsung Medical Center

Status and phase: Completed; Phase 2

Conditions: Locally Advanced Stage III or IV Thymic Cancer

Treatments: Drug: neoadjuvant docetaxel/cisplatin

Study type: Interventional

Funder types: Other

Identifiers

NCT01312324

2007-01-040

Details and patient eligibility

About

We try to evaluate whether neoadjuvant docetaxel plus cisplatin can increase the complete resection rate in advanced thymic carcinoma.

Enrollment: 27 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• histologically confirmed thymic carcinoma
• surgically inoperable Masaoka stage III or IV
• ECOG 0-2
• at least one measurable disease

Exclusion criteria

• previous myocardiac infarct history within 1 year before the enrollment.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

27 participants in 1 patient group

neoadjuvant chemotherapy

Experimental group

Description:

3 cycles of docetaxel/cisplatin before operation

Treatment:

Drug: neoadjuvant docetaxel/cisplatin